125 related articles for article (PubMed ID: 15830012)
21. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
23. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage.
Hoyer JD; Grogg KL; Hanson CA; Gamez JD; Dogan A
Am J Clin Pathol; 2008 Feb; 129(2):316-23. PubMed ID: 18208813
[TBL] [Abstract][Full Text] [Related]
24. Acute lymphoblastic leukemia accompanied by chromosomal abnormality of translocation (12;17).
Asahara SI; Saigo K; Hasuike N; Tamura M; Maeda Y; Tomofuji Y; Chinzei T; Tatsumi E
Haematologia (Budap); 2001; 31(3):209-13. PubMed ID: 11855782
[TBL] [Abstract][Full Text] [Related]
25. [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia].
Chen LJ; Li JY; Wu YJ; Yang H; Qian SX; Wu HX; Lu H; Xu W; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):692-5. PubMed ID: 17708784
[TBL] [Abstract][Full Text] [Related]
26. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome.
Amirghofran Z; Daneshbod Y; Gholijani N
Oncol Res; 2009; 17(10):447-54. PubMed ID: 19725224
[TBL] [Abstract][Full Text] [Related]
28. t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.
Krance RA; Raimondi SC; Dubowy R; Estrada J; Borowitz M; Behm F; Land VJ; Pullen J; Carroll AJ
Leukemia; 1992 Apr; 6(4):251-5. PubMed ID: 1534130
[TBL] [Abstract][Full Text] [Related]
29. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation.
Balduzzi A; Rossi V; Corral L; Bonanomi S; Longoni D; Rovelli A; Conter V; Biondi A; Uderzo C
Leukemia; 2003 Nov; 17(11):2247-8. PubMed ID: 12960967
[No Abstract] [Full Text] [Related]
30. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
Boldt DH; Kopecky KJ; Head D; Gehly G; Radich JP; Appelbaum FR
Leukemia; 1994 Dec; 8(12):2118-26. PubMed ID: 7807999
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients.
Maecker B; Mougiakakos D; Zimmermann M; Behrens M; Hollander S; Schrauder A; Schrappe M; Welte K; Klein C
Leukemia; 2006 Apr; 20(4):645-9. PubMed ID: 16498391
[TBL] [Abstract][Full Text] [Related]
32. Acute undifferentiated leukemia with an unusual CD7+ CD56+ CD33+ immunophenotype of NK progenitors.
Reuss-Borst MA; Jaschonek K; Müller CA
Leukemia; 1996 May; 10(5):923-4. PubMed ID: 8656693
[No Abstract] [Full Text] [Related]
33. Internalization of human macrophage surface antigens induced by monoclonal antibodies.
Audran R; Drenou B; Wittke F; Gaudin A; Lesimple T; Toujas L
J Immunol Methods; 1995 Dec; 188(1):147-54. PubMed ID: 8551032
[TBL] [Abstract][Full Text] [Related]
34. The prognostic impact of myeloid antigen expression in pediatric acute lymphoblastic leukemia patients.
Unal S; Cetin M; Tuncer AM; Gümrük F; Yetgin S
Turk J Pediatr; 2008; 50(6):533-6. PubMed ID: 19227415
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies in the treatment of myelogenous leukemias.
Scheinberg DA
Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876
[No Abstract] [Full Text] [Related]
36. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells.
Vitale C; Romagnani C; Falco M; Ponte M; Vitale M; Moretta A; Bacigalupo A; Moretta L; Mingari MC
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15091-6. PubMed ID: 10611343
[TBL] [Abstract][Full Text] [Related]
37. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia.
Drexler HG; Thiel E; Ludwig WD
Leukemia; 1991 Aug; 5(8):637-45. PubMed ID: 1886419
[TBL] [Abstract][Full Text] [Related]
38. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
Miller JL
Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
[No Abstract] [Full Text] [Related]
39. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.
Robillard N; Wuillème S; Lodé L; Magrangeas F; Minvielle S; Avet-Loiseau H
Leukemia; 2005 Nov; 19(11):2021-2. PubMed ID: 16167057
[No Abstract] [Full Text] [Related]
40. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling.
Lajaunias F; Dayer JM; Chizzolini C
Eur J Immunol; 2005 Jan; 35(1):243-51. PubMed ID: 15597323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
